Incyte's results for Q3 2026 (quarter ended Sep 30, 2026) come from the company's own earnings release, filed with the SEC on 2026-10-29. Everything below is taken from that filing; quotes are copied exactly. Company outlooks are the company's own.
At a glance
| Item | Value |
|---|---|
| Revenue (GAAP) | $1,557 million (+14.0% vs a year earlier) |
| Diluted EPS (GAAP) | $-3.86 |
| Adjusted per-share figure (company's non-GAAP measure; FFO/AFFO for REITs) | $-3.60 |
| Full-year guidance | Raised |
Guidance
Incyte raised 2026 total net sales guidance to $5,210–$5,300 million, with higher Opzelura and Hematology/Oncology ranges; Jakafi and expense guidance unchanged.
Why this label: 'raising its full year 2026 net sales guidance' for total net sales to $5,210-5,300M (from $5,130-5,260M); 'reaffirming' all other categories; no EPS guide.
| Metric | Period | New | Prior (as stated in the release) |
|---|---|---|---|
| total net sales | FY2026 | $5,210–$5,300 million | $5,130–$5,260 million |
| Opzelura net sales | FY2026 | $1,100–$1,120 million | $1,050–$1,100 million |
| Hematology and Oncology net sales | FY2026 | $890–$910 million | $860–$890 million |
| Jakafi net sales | FY2026 | $3,220–$3,270 million (unchanged) | $3,220–$3,270 million |
| total GAAP R&D and SG&A operating expenses | FY2026 | $4,915–$4,995 million (unchanged) | $4,915–$4,995 million |
From the release
Revenue: "Total GAAP revenues · $ · 1,557,204 · $ · 1,365,980"
Earnings per share: "GAAP diluted EPS 1 · $ · (3.86) · $ · 2.11 · $ · 0.50 · $ · 4.95 · Non-GAAP diluted EPS 1 · $ · (3.60)"
total net sales: "Total net sales · $5,210 - $5,300 million · $5,130 - $5,260 million"
Opzelura net sales: "Opzelura net sales (2) · $1,100 - $1,120 million · $1,050 - $1,100 million"
Hematology and Oncology net sales: "Hematology and Oncology net sales (3) · $890 - $910 million · $860 - $890 million"
Quotes are copied from the filing; in table rows, cell borders are shown as “·”.
Key fact: Raised 2026 total net sales guidance to $5.21–$5.30 billion; Q3 revenue rose 14%.
Source
Incyte earnings release (SEC filing), accession 0000879169-26-000063, filed 2026-10-29.
Part of the Q3 2026 Guidance Tracker. Educational only, not advice. Free weekly recap every Sunday: yieldterminalpro.com/newsletter.